Safety doubts unwarranted, important anti-malarial drug is safe to use, study finds

June 11, 2018, Mahidol Oxford Tropical Medicine Research Unit
Credit: ResearchSEA

One of the world's most widely used anti-malarial drugs is safe to use, say researchers, after a thorough review and analysis of nearly 200,000 malaria patients who'd taken the drug dihydroartemisinin-piperaquine (DHA-PPQ).

There is such a low risk of from DHA-PPQ, one of the world's most effective medicines to treat malaria, that there is no need to limit its current use, the researchers say in a study published today in The Lancet Infectious Diseases.

"There had been some concerns that DHA-piperaquine could be toxic for the heart. This very large study provides reassurance about the safety of one of our most important antimalarial drugs," said study senior author University of Oxford Prof Sir Nick White, Chairman of the Wellcome Trust Southeast Asia Research Units.

Used to treat P. falciparum and P. vivax malaria in Africa and Asia and in large-scale pilot programmes to eliminate malaria, DHA-PPQ is a highly efficacious and well-tolerated oral artemisinin combination treatment (ACT) medication that is on the WHO's List of Essential Medicines. Although DHA-PPQ has been used to treat more than 5.4 million people since its use was approved in Europe in 2011, there were concerns its use could lead to potentially lethal heart arrhythmias and sudden cardiac .

After carefully examining 96 studies, totalling 197,867 people who'd taken DHA-PPQ, researchers found one potentially drug-related sudden death. They concluded that the risk of sudden unexplained death after DHA-PPQ was no higher than the baseline rate for sudden cardiac death in the general population – and therefore that there was no reason to limit the use of DHA-PPQ.

"This analysis of almost 200,000 malaria patients treated with DHA-piperaquine provides the definite answer and reassuring message that the cardiac effects of piperaquine are not related to life threatening cardiac events and that DHA-PPQ is very safe to use," said University of Oxford Prof Arjen Dondorp, Deputy Director and Head of Malaria of the Bangkok-based Mahidol Oxford Tropical Medicine Research Unit (MORU).

"This study is important: It clearly shows no evidence of increased cardiac mortality associated with DHA-piperaquine therapy in large population studies. It certifies the safety of using DHA-PPQ as a preventive strategy. The next step should be prospective studies to confirm these very reassuring results," said cardiologist and study co-author Prof Josep Brugada of the University of Barcelona.

The study results were hailed by people active in the global fight against , a parasitic disease transmitted by mosquitoes that killed 445,000 people in 2016, most of them children in Africa.

Michael Chew, from Wellcome's Infection and Immunobiology team, said: "DHA-PPQ is one of the most effective and widely used anti-malarial drugs we have today, and concerns it could lead to abnormal heart rhythms risked limiting its use and impact. This important study confirms that this drug is safe to use, as the risk of in patients not higher than in the general population."

Explore further: Superbug's spread to Vietnam threatens malaria control

More information: Pere Millat-Martínez et al. Reappraising the cardiosafety of dihydroartemisinin-piperaquine, The Lancet Infectious Diseases (2018). DOI: 10.1016/S1473-3099(18)30360-8

Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis. The Lancet Infectious Diseases, DOI: doi.org/10.1016/S1473-3099(18)30297-4

Related Stories

Superbug's spread to Vietnam threatens malaria control

September 21, 2017
A highly drug resistant malaria 'superbug' from western Cambodia is now present in southern Vietnam, leading to alarming failure rates for dihydroartemisinin (DHA)-piperaquine—Vietnam's national first-line malaria treatment, ...

Malaria superbugs threaten global malaria control

February 1, 2017
A lineage of multidrug resistant P. falciparum malaria superbugs has widely spread and is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for the main falciparum malaria medicines, ...

Two genetic markers that predict malaria treatment failure found

November 3, 2016
Scientists at the Wellcome Trust Sanger Institute and their collaborators have discovered genetic markers in malaria parasites linked with resistance to the anti-malarial drug piperaquine. Reported in Lancet Infectious Diseases, ...

Current malaria treatment fails in Cambodia due to drug-resistant parasites

January 7, 2016
New findings from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), confirm dihydroartemisinin-piperaquine, the first-line treatment for Plasmodium falciparum ...

Cochrane review of dihydroartemisinin-piperaquine for treating uncomplicated malaria

January 21, 2014
'Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine' concludes a systematic review published by the Cochrane Infectious Disease Group, hosted ...

Increased dosing of malaria drug in children could decrease risk of infection

October 30, 2014
Piperaquine is a long-acting malaria drug that kills residual parasites and decreases the risk of reinfection. A study led by Uppsala University researcher Martin Bergstrand shows that increasing the dose used in children ...

Recommended for you

Study reveals new therapeutic target for slowing the spread of flu virus

June 22, 2018
Influenza A (flu A) hijacks host proteins for viral RNA splicing and blocking these interactions caused replication of the virus to slow, according to new research published in Nature Communications by Kristin W. Lynch, Ph.D., ...

First ancient syphilis genomes decoded

June 21, 2018
An international research team, including scientists from the Max Planck Institute for the Science of Human History, the University of Tübingen, the National School of Anthropology and History in Mexico City, and the University ...

Rhesus macaque model offers route to study Zika brain pathology

June 21, 2018
Rhesus macaque monkeys infected in utero with Zika virus develop similar brain pathology to human infants, according to a report by researchers at the California National Primate Research Center and School of Veterinary Medicine ...

California Aedes mosquitoes capable of spreading Zika

June 21, 2018
Over the last five years, Zika virus has emerged as a significant global human health threat following outbreaks in South and Central America. Now, researchers reporting in PLOS Neglected Tropical Diseases have shown that ...

Breakthrough treatment for crippling jaw disease created

June 20, 2018
A first-ever tissue implant to safely treat a common jaw defect, known as temporomandibular joint dysfunction, has been successfully tested by UCI-led researchers in a large animal model, according to new findings.

Cell-free DNA profiling informative way to monitor urinary tract infections

June 20, 2018
Using shotgun DNA sequencing, Cornell University researchers have demonstrated a new method for monitoring urinary tract infections (UTIs) that surpasses traditional methods in providing valuable information about the dynamics ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.